Nxera Pharma Co., Ltd. (TYO:4565)
905.00
+54.00 (6.35%)
At close: Mar 6, 2026
Nxera Pharma Employees
Nxera Pharma had 382 employees as of December 31, 2025. The number of employees increased by 8 or 2.14% compared to the previous year.
Employees
382
Change
8
Growth
2.14%
Revenue / Employee
77.53M JPY
Profits / Employee
-32.80M JPY
Market Cap
81.90B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 382 | 8 | 2.14% |
| Sep 30, 2025 | 384 | 12 | 3.23% |
| Jun 30, 2025 | 389 | 29 | 8.06% |
| Mar 31, 2025 | 387 | 23 | 6.32% |
| Dec 31, 2024 | 374 | 24 | 6.86% |
| Sep 30, 2024 | 372 | 24 | 6.90% |
| Jun 30, 2024 | 360 | 149 | 70.62% |
| Mar 31, 2024 | 364 | 157 | 75.85% |
| Dec 31, 2023 | 350 | 148 | 73.27% |
| Sep 30, 2023 | 348 | 149 | 74.87% |
| Jun 30, 2023 | 211 | 6 | 2.93% |
| Mar 31, 2023 | 207 | 10 | 5.08% |
| Dec 31, 2022 | 202 | 4 | 2.02% |
| Sep 30, 2022 | 199 | 3 | 1.53% |
| Jun 30, 2022 | 205 | 17 | 9.04% |
| Mar 31, 2022 | 197 | 4 | 2.07% |
| Dec 31, 2021 | 198 | 8 | 4.21% |
| Sep 30, 2021 | 196 | 12 | 6.52% |
| Jun 30, 2021 | 188 | 18 | 10.59% |
| Mar 31, 2021 | 193 | 30 | 18.40% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Takara Bio | 1,779 |
| GNI Group | 867 |
| PeptiDream | 751 |
| Japan Tissue Engineering | 204 |
| Healios K.K. | 65 |
| RaQualia Pharma | 64 |
| Cuorips | 56 |
| AnGes | 55 |
Nxera Pharma News
- 2 days ago - Nxera Pharma to Receive US$3 Million Milestone Payment from Centessa Pharmaceuticals - GlobeNewsWire
- 3 days ago - Nxera Pharma Submits Marketing Authorization Application for Daridorexant in South Korea - GlobeNewsWire
- 21 days ago - Nxera Pharma Co., Ltd. (SOLTF) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 21 days ago - Nxera Pharma Proposes Changes to its Board of Directors - GlobeNewsWire
- 22 days ago - Nxera Pharma Operational Highlights and Consolidated Results for the Fourth Quarter and Full Year 2025 - GlobeNewsWire
- 23 days ago - Nxera Pharma to Receive $1.8 Million Milestone Payment from Centessa Pharmaceuticals - GlobeNewsWire
- 23 days ago - Nxera Pharma Licenses GPCR-targeted Program to Newly Founded Spin-out Company - GlobeNewsWire
- 7 weeks ago - Nxera Pharma Co., Ltd. (SOLTF) Presents at 44th Annual J.P. - Seeking Alpha